Adalimumab treatment in children with refractory crohn's disease

Yoram Rosenbach, Corina Hartman, Rivka Shapiro, Akiva Hirsch, Yaron Avitzur, Raanan Shamir

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Information on safety and efficacy of adalimumab in children with Crohn's disease (CD) is limited. We present a case-series of 14 children with severe CD treated with adalimumab during a 3.5-year period. Fourteen children (nine boys, five girls), aged 13.9 years (range 1.9-19.1) were treated with adalimumab during 12.5 months (range 7-42). All had steroid or immunosuppression-drugs refractory disease. Ten patients (71%) had been previously treated with infliximab, 13/14 were treated with different immunosuppressive drugs and all were steroid-dependent or resistant. Seven children (50%) showed full clinical response and 5/14 (35%) improved partially. Two children (15%) had loss of response after a period of transient improvement. Adalimumab treatment enabled complete steroids withdrawal in 8/14 (57%) of steroid-dependent children. Currently, five children are in complete remission with adalimumab monotherapy for a median 14 months (range 9-24). Adalimumab may induce and maintain remission in children with severe, refractory CD. Prospective safety and efficacy confirmation of this data in children is necessary.

Original languageEnglish
Pages (from-to)747-753
Number of pages7
JournalDigestive Diseases and Sciences
Issue number3
StatePublished - Mar 2010
Externally publishedYes


  • Adalimumab
  • Children
  • Crohn's disease
  • Infliximab


Dive into the research topics of 'Adalimumab treatment in children with refractory crohn's disease'. Together they form a unique fingerprint.

Cite this